A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Novartis
Eastern Cooperative Oncology Group
Essen Biotech
Fred Hutchinson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Blue Note Therapeutics
Fred Hutchinson Cancer Center
University of Wisconsin, Madison
Incyte Corporation
Henry Ford Health System
Butler Hospital
University of Kansas Medical Center
Alliance for Clinical Trials in Oncology
Michigan State University
Wake Forest University Health Sciences
Roswell Park Cancer Institute
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
Fox Chase Cancer Center
University of Washington
Vanderbilt University
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)